1. Introduction {#sec1-cancers-12-00551}
===============

Gastric cancer (GC) ranks as the sixth most common cancer and the second leading cause of cancer-related deaths \[[@B1-cancers-12-00551]\]. According to The Cancer Genome Atlas (TCGA) \[[@B2-cancers-12-00551]\], GC is classified into four types: (1) Epstein--Barr virus (EBV) positive, (2) microsatellite instability-high (MSI-H), (3) genomically stable, and (4) GC with chromosomal instability. Immunotherapy has been shown to have a better disease control rate in GC patients with MSI-H tumors than in those with microsatellite stable (MSS) tumors \[[@B3-cancers-12-00551]\]. Elevated microsatellite alterations at selected tetranucleotide repeats (EMAST), a variant of MSI with a prevalence ranging from 9% to 75% \[[@B4-cancers-12-00551]\], have been reported in various cancers. To date, there has been no report regarding EMAST status in GC.

In colorectal cancer, the incidence of EMAST was similar to that of MSI and was approximately 20%--40%; EMAST+ tumors were associated with the MSI-H phenotype and more frequently located in the colon than in the rectum \[[@B5-cancers-12-00551],[@B6-cancers-12-00551]\]. However, in non-small cell lung cancer \[[@B7-cancers-12-00551]\], the incidence of EMAST was higher than that of MSI (42.9% vs. 16.3%), and there was no association between the incidence rates of EMAST and MSI. The correlation between EMAST status and patient survival in cancer is still controversial \[[@B5-cancers-12-00551],[@B6-cancers-12-00551],[@B7-cancers-12-00551],[@B8-cancers-12-00551]\]. Consequently, there is a need to investigate the correlation among EMAST status, MSI status, genetic alterations, and clinicopathological features in GC patients.

In our previous study \[[@B9-cancers-12-00551]\], we designed a 16 DNA-repair-associated gene panel, using next-generation sequencing (NGS), to investigate the clinical impact of EMAST/MSI status in colorectal cancer. We found that, in MSI-H colorectal cancer, EMAST+ tumors were associated with a better prognosis than EMAST− tumors. In this study, we used a 16-gene panel to study the correlation between the clinicopathological features, the mutation profiling of DNA-repair-associated genes and of common GC-related genes, and the prognosis of GC patients according to the EMAST and MSI status.

2. Results {#sec2-cancers-12-00551}
==========

Among the 360 patients, 76 (21.1%) had EMAST+ tumors and 284 had EMAST− tumors; and 59 (16.4%) tumors were MSI-H, and 301 were MSS. According to the EMAST/MSI status, there were 35 EMAST+/MSI-H, 41 EMAST+/MSS, 24 EMAST−/MSS, and 260 EMAST−/MSS tumors.

2.1. Clinicopathological Profiles {#sec2dot1-cancers-12-00551}
---------------------------------

As shown in [Table 1](#cancers-12-00551-t001){ref-type="table"}, patients with EMAST+ tumors had fewer Borrmann type 3 and 4 tumors, fewer Helicobacter pylori (HP) infections, earlier pathological T categories, and more genetic mutations in the *PI3K*/*AKT* pathway and in *ARID1A* than those with EMAST− tumors. Low expression of MSH3 by IHC staining was not significantly different between patients with EMAST+ tumors and patients with EMAST− tumors (28.9% vs. 27.8%). Patients with MSI-H tended to be older, have a larger tumor size, have more EBV infections, have fewer HP infections, and have more genetic mutations in the *PI3K*/*AKT* pathway than those with MSS.

As shown in [Table 2](#cancers-12-00551-t002){ref-type="table"}, patients with EMAST+/MSI-H tumors had an earlier pathological T category, earlier pathological TNM stage, and had fewer Borrmann type 3 and 4 tumors than the other three GC subtypes.

2.2. Mutational Profiling of GC Subtypes According to EMAST/MSI Status {#sec2dot2-cancers-12-00551}
----------------------------------------------------------------------

Mutation profiling of DNA-repair-associated genes, using NGS analysis, was performed for 160 patients, according to their EMAST/MSI status. As shown in [Table 3](#cancers-12-00551-t003){ref-type="table"}, EMAST+ tumors were associated with a significantly higher frequency of genetic mutations than EMAST− tumors in *EXO1*, *EPCAM*, *MSH2*, *TGFBR2*, *MLH1*, *MSH3*, *POLE*, *AXIN1*, *AXIN2*, and *BAX*. MSI-H tumors showed a significantly higher frequency of genetic mutations than MSS tumors in *EXO1*, *EPCAM*, *PMS1*, *TGFBR2*, and *BAX*, while MSS tumors showed a significantly higher frequency of genetic mutations than MSI-H tumors in *CTNNB1*.

As shown in [Table 4](#cancers-12-00551-t004){ref-type="table"}, EMAST+/MSI-H tumors demonstrated a significantly higher frequency of genetic mutations in *EXO1*, *EPCAM*, *MSH2*, *MSH6*, *TGFBR2*, *AXIN1*, and *BAX* than the other three subtypes. EMAST+/MSS tumors showed a significantly higher frequency of genetic mutations in *MSH3* and *POLE* than the other three subtypes.

2.3. Initial Recurrence Patterns {#sec2dot3-cancers-12-00551}
--------------------------------

Among the 360 patients, 275 patients receiving curative surgery were enrolled in the analysis of initial recurrence patterns. As shown in [Table 5](#cancers-12-00551-t005){ref-type="table"}, patients with EMAST+ tumors had fewer distant metastases (8.6% vs. 20.7%, *p* = 0.034) than those with EMAST− tumors. There was no significant difference in the initial recurrence pattern between patients with MSI-H tumors and patients with MSS tumors.

As shown in [Table 6](#cancers-12-00551-t006){ref-type="table"}, patients with EMAST−/MSI-H tumors had significantly more tumor recurrence than the other subtypes (EMAST−/MSI-H: 50%, EMAST+/MSS: 31.0%, EMAST−/MSS: 25.9%, EMAST+/MSI-H: 0%, *p* = 0.001). Among the initial recurrence patterns, patients with EMAST−/MSI-H tumors were associated with the highest distant metastasis rates compared to the other three GC subtypes, especially peritoneal recurrence.

2.4. Survival Analysis {#sec2dot4-cancers-12-00551}
----------------------

The five-year overall survival (OS) rates were not significantly different between patients with EMAST+ and patients with EMAST− tumors (65.5% vs. 60.2%, *p* = 0.689), or between patients with MSI-H and patients with MSS tumors (60.0% vs. 61.6%, *p* = 0.793).

As shown in [Figure 1](#cancers-12-00551-f001){ref-type="fig"}, among the 275 patients receiving curative surgery, the five-year OS rates were the highest in patients with EMAST+/MSI-H (72.4%), followed by EMAST−/MSS (62.1%), EMAST+/MSS (58.6%), and EMAST−/MSI-H (37.5%). Among the four GC subtypes, patients with EMAST+/MSI-H had significantly higher five-year OS rates compared with patients with EMAST−/MSI-H tumors (72.4% vs. 37.5%, *p* = 0.046). There was no significant difference in five-year OS rates between other GC subtypes.

As shown in [Table 7](#cancers-12-00551-t007){ref-type="table"}, multivariate analysis showed that lymphovascular invasion, Lauren's classification, and pathological TNM stage were independent prognostic factors affecting OS. Multivariate analysis demonstrated that lymphovascular invasion, Lauren's classification and pathological TNM stage were independent prognostic factors affecting disease-free survival (DFS) ([Table 7](#cancers-12-00551-t007){ref-type="table"}).

2.5. Subgroup Analysis for MSI-H GC {#sec2dot5-cancers-12-00551}
-----------------------------------

For clinicopathological features of MSI-H GC, EMAST+ tumors showed fewer Borrmann type 3 and 4 tumors, less lymphovascular invasion, more lymphoid stroma, earlier pathological T and N categories, and earlier TNM stages than EMAST− tumors.

Regarding the mutational profiling in MSI-H GC, EMAST+ tumors showed a significantly higher frequency of genetic mutations in *MSH2*, *AXIN1*, and *POLD1* than EMAST− tumors.

For the initial recurrence pattern and survival analysis for MSI-H GC patients receiving curative surgery, EMAST+ tumors showed less tumor recurrence and a better five-year OS rate than EMAST− tumors.

3. Discussion {#sec3-cancers-12-00551}
=============

To the best of our knowledge, this study is the first to investigate the clinical impact of EMAST status on genetic alterations and clinicopathological features in GC. Our results demonstrated that *PI3K*/*AKT* pathway mutations were more frequent in EMAST+ and/or MSI-H tumors. Neither EMAST status nor MSI status was an independent prognostic factor. Subgroup analysis for MSI-H GC showed that EMAST+ tumors were associated with more favorable clinicopathological features and better survival than EMAST− tumors, demonstrating that EMAST+ and EMAST− tumors are different entities in MSI-H GC.

It was reported that EMAST was associated with the loss of MSH3 nuclear expression in colorectal cancer \[[@B10-cancers-12-00551]\], while no significant correlation between EMAST and loss of MSH3 expression was reported in pancreas cancer \[[@B11-cancers-12-00551]\]. Although our results demonstrated that EMAST status was not associated with low expression of MSH3, the frequency of MSH3 mutation in EMAST+/MSI-H and EMAST+/MSS tumors was 23.5% and 27.5%, which was significantly higher than that in EMAST−/MSI-H and EMAST−/MSS tumors (8.3% and 3.8%). The MSH3 mutation might play an important role in EMAST status in GC.

In the present study, regarding the 16 DNA-repair-associated genes, EMAST+/MSI-H tumors had a higher frequency of *EXO1*, *EPCAM*, *MSH2*, *MSH6*, *TGFBR2*, *AXIN1*, and *BAX* than the other three GC subtypes. Our previous study \[[@B9-cancers-12-00551]\] regarding mutations in DNA-repair-associated genes in colorectal cancer demonstrated that EMAST+/MSI-H tumors had a higher frequency of *MLH1*, *MSH3*, *MSH6*, *PMS2*, and *EXO1* genetic mutations than the other three colorectal cancer subtypes. Comparing the results of the present study and our previous study \[[@B9-cancers-12-00551]\] in colorectal cancer, we observed that *MSH6* and *EXO1* genetic mutations were higher in EMAST+/MSI-H tumors than other subtypes, in both GC and colorectal cancer. It seems that *MSH6* and *EXO1* genetic mutations play an important role in gastrointestinal tract cancer with the EMAST+/MSI-H phenotype. Because there have been no reports investigating the differences in DNA-repair-associated genetic mutations among GC patients according to the EMAST/MSI status, our results might provide useful information for future studies in this field. More patients encompassing different races enrolled from different countries and further in vivo and in vitro studies are required to validate our results.

Although immunotherapy was approved by the US Food and Drug Administration for MSI-H tumors, the response rate was approximately 30%--40% \[[@B12-cancers-12-00551],[@B13-cancers-12-00551]\]. The most important finding of the present study is that, for MSI-H GC patients, EMAST+ tumors were associated with more favorable clinicopathological features, a better prognosis, and a higher frequency of genetic mutations in *MSH2*, *AXIN1*, and *POLD1* compared with EMAST− tumors. Consequently, the higher frequency of several DNA-repair-associated genetic mutations in EMAST+/MSI-H than EMAST−/MSI-H tumors demonstrated that combined EMAST/MSI status may be more promising than MSI status alone for the application of immunotherapy in GC treatment, which was similar to the findings of our previous study in colorectal cancer \[[@B9-cancers-12-00551]\]. For validation of our results and hypothesis, more patients enrolled from different countries and clinical trials are required for the application of EMAST/MSI status on the immunotherapy for GC patients.

In the present study, for MSS GC, the status of EMAST does not correlate with patient prognosis. There are two possible reasons. First, the patient number is limited and the difference is not easy to reach statistical significance. Second, in comparison with the major role of MSI status associated with a better prognosis, EMAST phenotype may play as an additional effect on improved prognosis. Only for MSI-H GC, EMAST+ tumors were associated with significantly more DNA-repair-associated genetic mutations than EMAST− tumors, which may cause immune response and improve patient survival.

In previous studies \[[@B14-cancers-12-00551],[@B15-cancers-12-00551]\], Corso G et al demonstrated that MSI-H GC had distinct clinicopathological features and frequently showed activation of *PI3K/AKT* pathway compared with MSS GC, which was similar to our findings ([Table 1](#cancers-12-00551-t001){ref-type="table"}). Furthermore, one of another important findings is that *PI3K*/*AKT* pathway mutations were more frequent in EMAST+ tumors than in EMAST− tumors, which was also observed in the MSI-H tumors than in MSS tumors ([Table 1](#cancers-12-00551-t001){ref-type="table"}). Our previous study \[[@B9-cancers-12-00551]\] in colorectal cancer also demonstrated a higher incidence of mutations in *PI3K*/*AKT* pathway genes (*PIK3CA*, *PTEN*, and *AKT1*) in the EMAST+/MSI-H tumors than in other subtypes. It was reported that upregulation of *PI3K/AKT* pathway was observed in tumors with mismatch repair deficiency, including MSH2-mutant tumors \[[@B16-cancers-12-00551]\]. In addition, overexpression of *AXIN1* protected against tumors via inhibiting the PI3K/AKT pathway \[[@B17-cancers-12-00551]\]. We speculate that mutations of *MSH2* and *AXIN1* may be involved in the *PI3K/AKT* pathway and play an important role in both EMAST+ and MSI-H tumors originating from gastrointestinal tract cancer. Further in vivo and in vitro studies are required to investigate the mechanism between EMAST status, MSI status, *MSH2*, *AXIN1*, and *PI3K*/*AKT* pathway in GC. Our findings might have clinical impact on the targeted therapy for EMAST+ and MSI-H GC.

There are some limitations in the present study. First, it is a retrospective study, and selection bias exists. Second, although significant survival difference was observed between the EMAST+/MSI-H group and EMAST−/MSI-H group, the patient number enrolled in the present study was limited, and more patients are required for the validation of our results. We hope our findings can have a clinical impact on immunotherapy and targeted therapy for GC treatment in the future.

4. Materials and Methods {#sec4-cancers-12-00551}
========================

4.1. Patients and Tissue Collection {#sec4dot1-cancers-12-00551}
-----------------------------------

The normal and tissue samples of 360 GC patients who underwent curative surgery were obtained from the biobank of our hospital. After surgery, tumor and normal tissues were collected and immediately frozen and stored in liquid nitrogen. The study was approved by the Ethical Committee of Taipei Veterans General Hospital (Number: 2017-12-012CC). The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all study participants.

The clinical data, including age, gender, tumor location, TNM stage, differentiation, pathological prognostic features, and follow-up conditions, were prospectively collected. After surgery, patients were followed up quarterly for the first 3 years and then semiannually thereafter. The follow-up examinations included panendoscopy, serum tumor markers (CEA, CA19-9), chest radiography, and sonography or computed tomography of the abdomen.

DNA samples were extracted from freshly frozen tumors and normal tissues (surgical resection margins or normal tissues were sampled distant from the primary tumor site), using the QIACUBE (Qiagen, Cat.51306, Hilden, Germany) instrument and dedicated reagents and kits, according to the manufacturer's instructions.

4.2. Analysis of MSI and EMAST Statuses {#sec4dot2-cancers-12-00551}
---------------------------------------

According to international criteria, five reference microsatellite markers were used to determine MSI status: D5S345, D2S123, BAT25, BAT26, and D17S250. The MSI method was the same as that described in a previous report \[[@B18-cancers-12-00551]\]. Samples with two or more MSI markers were defined as MSI-H, and those with one or no MSI markers were classified as MSS.

As described in a previous study \[[@B19-cancers-12-00551]\], five tetranucleotide microsatellite markers were used to determine EMAST status: (MYCL1, D9S242, D20S85, D8S321, and D20S82). If two or more of the 5 markers showed instability, tumors were defined as EMAST+; if none or one of the markers showed instability, the tumor was considered to be EMAST−.

4.3. Identification of HP and EBV Infection {#sec4dot3-cancers-12-00551}
-------------------------------------------

The methods for identifying HP and EBV infection were the same as those described in a previous report \[[@B20-cancers-12-00551]\]. HP infection was identified by polymerase chain reaction (PCR), and EBV infection was detected by using the Sequenom MassARRAY system.

4.4. Identification of PIK3CA Amplification {#sec4dot4-cancers-12-00551}
-------------------------------------------

As described in a previous study \[[@B21-cancers-12-00551]\], the copy number of the PIK3CA gene was analyzed by quantitative real-time PCR, and the LINE1 element was used as an internal reference target, using primer sequences. Copy number amplification of the PIK3CA gene was defined by a copy number ≥3 with a *p*-value \<0.05.

4.5. Mutation Analysis of Common GC-related Genes Based on MassARRAY {#sec4dot5-cancers-12-00551}
--------------------------------------------------------------------

As described in a previous study \[[@B22-cancers-12-00551]\], a nine-gene panel using MassARRAY was performed for mutation analysis of common GC-related genes in all 360 GC patients enrolled, including *TP53*, *ARID1A*, *PTEN*, *PIK3CA*, *AKT1*, *AKT2*, *AKT3*, *KRAS*, and *BRAF*. Among them, mutations in the *PI3K*/*AKT* pathway were identified in at least any one of the following genes: *PTEN*, *PIK3CA*, *AKT1*, *AKT2*, and *AKT3*.

4.6. Next-Generation Sequencing {#sec4dot6-cancers-12-00551}
-------------------------------

As described in our previous study \[[@B9-cancers-12-00551]\], we used the HiSeq2500 system (Illumina Inc., San Diego, CA, USA) to explore the DNA sequences of all exons of 16 well-known DNA-repair-related genes in 150 GC patients, including *AXIN1*, *AXIN2*, *BAX*, *CTNNB1*, *EPCAM*, *EXO1*, *MLH1*, *MSH2*, *MSH3*, *MSH6*, *PCNA*, *PMS1*, *PMS2*, *POLD1*, *POLE*, and *TGFBR2*.

4.7. Immunohistochemical Staining for MSH3 {#sec4dot7-cancers-12-00551}
------------------------------------------

Tissue sections of 5 µm thickness were deparaffinized, rehydrated, and pretreated with sodium citrate buffer (10 mM, pH 6.0), in a pressure cooker, at 121 °C, for 3 minutes. Immunohistochemical (IHC) staining was performed with the Novolink Poly Detection System (Cat.RE7280, Leica Biochemistry, Newcastle upon Tyne, UK), according to the manufacturer's instructions. The tissue sections were incubated at 4 °C overnight, with MSH3 primary antibody (Cat.ab111107, 1:500 dilution, Abcam, Cambridge, UK). The samples were developed with DAB chromogen and then counterstained with hematoxylin. The slides were mounted, using DPX Mountant for histology (Cat.44581, Sigma, Gillingham, UK). As defined in previous reports \[[@B8-cancers-12-00551],[@B23-cancers-12-00551]\], low MSH3 protein expression was defined as \<85% brown staining of cell cores in tumor cells, and high MSH3 protein expression was defined as ≥85% brown staining of cell cores in tumor cells.

4.8. Statistical Analysis {#sec4dot8-cancers-12-00551}
-------------------------

Statistical analyses were performed by using IBM SPSS version 25.0. Categorical data were compared, using a χ2 test, with Yates correction or Fisher's exact test. OS was measured from the operation date to the date of death or the final follow-up. DFS was defined as the length of time after surgery during which a patient survived without GC recurrence. The distributions of OS and DFS were estimated, using the Kaplan--Meier method. Multivariate analysis, using Cox proportional hazards models, was performed to explore the association of the clinical parameters with OS and DFS. A *p*-value of \<0.05 was considered to be statistically significant.

5. Conclusions {#sec5-cancers-12-00551}
==============

For MSI-H GC, EMAST+ tumors showed a more favorable prognosis and were associated with a higher frequency of several DNA-repair-associated genetic mutations than EMAST− tumors. EMAST+/MSI-H tumors are likely to be a different entity from EMAST−/MSI-H tumors. Combined EMAST/MSI status is recommended for the evaluation of immunotherapy for GC treatment. PI3K/AKT pathway mutations are more frequent in EMAST+ and/or MSI-H tumors than in EMAST−/MSS tumors. Further in vivo and in vitro studies are required to investigate of the correlation of EMAST/MSI status and genetic mutations in DNA-repair-associated genes and the PI3K/AKT pathway in GC. We hope our results can shed light on GC treatment, including immunotherapy and even targeted therapy.
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cancers-12-00551-t001_Table 1

###### 

Clinical profiles among patients according to the EMAST and MSI status.

  Clinical Profiles         EMAST Status   MSI Status                                          
  ------------------------- -------------- ------------ ------------- ------------ ----------- -------------
  Age (y/o)                                             0.327                                  **0.028**
  \<45                      20 (7.0)       3 (3.9)                    23 (7.6)     0           
  ≥45                       264 (93.0)     73 (96.1)                  278 (92.4)   59 (100)    
  Gender (M/F)              189/95         56/20        0.236         204/97       41/18       0.796
  Tumor size (\<5/≥5 cm)    98/186         21/55        0.258         107/194      12/47       **0.023**
  Cell differentiation                                  0.929                                  0.559
  Poor                      162 (57.0)     43 (56.6)                  174 (57.8)   31 (52.5)   
  Moderate                  119 (41.9)     44 (43.4)                  124 (41.2)   28 (47.5)   
  Well                      3 (1.1)        0                          3 (1.0)      0           
  Gross appearance                                      **0.005**                              0.510
  Superficial type          18 (6.3)       8 (10.5)                   24 (8.0)     2 (3.4)     
  Borrmann type 1 and 2     74 (26.1)      32 (42.1)                  87 (28.9)    19 (32.2)   
  Borrmann type 3 and 4     192 (67.6)     36 (47.4)                  190 (63.1)   38 (64.4)   
  Lymphovascular invasion   201 (70.8)     52 (68.4)    0.690         208 (69.1)   45 (76.3)   0.271
  Lymphoid stroma           27 (9.5)       12 (15.8)    0.118         30 (10.0)    9 (15.3)    0.232
  EBV infection             33 (11.6)      12 (15.8)    0.329         33 (11.0)    12 (20.3)   **0.046**
  HP infection              104 (36.6)     11 (14.5)    **\<0.001**   105 (34.9)   10 (16.9)   **0.007**
  *PIK3CA* amplification    76 (26.8)      16 (21.1)    0.311         78 (25.9)    14 (23.7)   0.725
  Pathological T category                               **0.049**                              0.232
  T1                        32 (11.3)      11 (14.5)                  37 (12.3)    6 (10.2)    
  T2                        30 (10.6)      16 (21.1)                  34 (11.3)    12 (20.3)   
  T3                        125 (44.0)     31 (40.8)                  130 (43.2)   26 (44.1)   
  T4                        97 (34.2)      18 (23.7)                  100 (33.2)   15 (25.4)   
  Pathological N category                               0.121                                  0.911
  N0                        65 (22.9)      26 (34.2)                  77 (25.6)    14 (23.7)   
  N1                        42 (14.8)      14 (18.4)                  45 (15.0)    11 (18.6)   
  N2                        53 (18.7)      11 (14.5)                  54 (17.9)    10 (16.9)   
  N3                        124 (43.7)     25 (32.9)                  125 (41.5)   24 (40.7)   
  Pathological TNM Stage                                0.050                                  0.507
  I                         40 (14.1)      20 (26.3)                  48 (15.9)    12 (20.3)   
  II                        68 (23.9)      17 (22.4)                  75 (24.9)    10 (16.9)   
  III                       113 (48.9)     34 (44.7)                  142 (47.2)   31 (52.5)   
  IV                        37 (13.0)      5 (6.6)                    36 (12.0)    6 (10.2)    
  Genetic mutation                                                                             
  *PI3K/AKT* pathway        22 (7.7)       19 (25.0)    **\<0.001**   25 (8.3)     16 (27.1)   **\<0.001**
  *ARID1A*                  11 (3.9)       11 (14.5)    **0.001**     18 (6.0)     4 (6.8)     0.815
  *TP53*                    27 (9.5)       5 (6.6)      0.426         30 (10.0)    2 (3.4)     0.105
  *KRAS*                    8 (2.8)        3 (3.9)      0.611         7 (2.3)      4 (6.8)     0.069
  *BRAF*                    0              1 (1.3)      0.053         1 (0.3)      0           0.658

EMAST: elevated microsatellite alterations at selected tetranucleotide repeats; MSI-H: microsatellite instability-high; MSS: microsatellite stable; EBV: Epstein--Barr virus; HP: Helicobacter pylori. Bold: statistically significant

cancers-12-00551-t002_Table 2

###### 

Clinical profiles among patients according to the EMAST/MSI status.

  Clinical Profiles         EMAST/MSI Status                                        
  ------------------------- ------------------ ----------- ----------- ------------ -------------
  Age                                                                               0.117
  \<45 years                0                  3 (7.3)     0           20 (7.7)     
  ≥45 years                 35 (100)           38 (92.7)   24 (100)    240 (92.3)   
  Gender (M/F)              25/10              31/10       16/8        173/87       0.669
  Tumor size (\<5/≥5 cm)    8/27               13/28       4/20        94/166       0.126
  Cell differentiation                                                              0.889
  Poor                      23 (65.7)          20 (48.8)   8 (33.3)    154 (59.2)   
  Moderate                  12 (34.3)          21 (51.2)   16 (66.7)   103 (39.6)   
  Well                      0                  0           0           3 (1.2)      
  Gross appearance                                                                  **0.030**
  Superficial type          2 (5.7)            6 (14.6)    0           18 (6.9)     
  Borrmann type 1 and 2     17 (48.6)          15 (36.6)   2 (8.3)     72 (27.7)    
  Borrmann type 3 and 4     16 (45.7)          20 (48.8)   22 (91.7)   170 (65.4)   
  Lymphovascular invasion   23 (65.7)          29 (70.7)   22 (91.7)   179 (68.8)   0.118
  Lymphoid stroma           9 (25.7)           3 (7.3)     0           27 (10.4)    0.094
  EBV infection             6 (17.1)           6 (14.6)    6 (25.0)    27 (10.4)    0.197
  HP infection              6 (17.1)           5 (12.2)    4 (16.7)    100 (38.5)   **\<0.001**
  *PIK3CA* amplification    6 (17.1)           10 (24.4)   8 (33.3)    68 (26.2)    0.543
  Pathological T category                                                           **0.037**
  T1                        6 (17.1)           5 (12.2)    0           32 (12.3)    
  T2                        8 (22.9)           8 (19.5)    4 (16.7)    26 (10.0)    
  T3                        14 (40.0)          17 (41.5)   12 (50.0)   113 (43.5)   
  T4                        7 (20.0)           11 (26.8)   8 (33.3)    89 (34.2)    
  Pathological N category                                                           0.062
  N0                        12 (34.3)          14 (34.1)   2 (8.3)     63 (24.2)    
  N1                        7 (20.0)           7 (17.1)    4 (16.7)    38 (14.6)    
  N2                        6 (17.1)           5 (12.2)    4 (16.7)    49 (18.8)    
  N3                        10 (28.6)          15 (36.6)   14 (58.3)   110 (42.3)   
  Pathological TNM Stage                                                            **0.038**
  I                         10 (28.6)          10 (24.4)   2 (8.3)     38 (14.6)    
  II                        8 (22.9)           9 (22.0)    2 (8.3)     66 (25.4)    
  III                       15 (42.9)          19 (46.3)   16 (66.7)   123 (47.3)   
  IV                        2 (5.7)            3 (7.3)     4 (16.7)    33 (12.7)    
  Genetic mutation                                                                  
  *PI3K/AKT* pathway        8 (22.9)           11 (26.8)   8 (33.3)    14 (5.4)     **\<0.001**
  *ARID1A*                  2 (5.7)            9 (22.0)    2 (8.3)     9 (3.5)      **0.002**
  *TP53*                    0                  5 (12.2)    2 (8.3)     25 (9.6)     0.066
  *KRAS*                    2 (5.7)            1 (2.4)     2 (8.3)     6 (2.3)      0.422
  *BRAF*                    0                  1           0           0            0.224

EMAST: elevated microsatellite alterations at selected tetranucleotide repeats; MSI-H: microsatellite instability-high; MSS: microsatellite stable; EBV: Epstein--Barr virus; HP: Helicobacter pylori. Bold: statistically significant.

cancers-12-00551-t003_Table 3

###### 

Genetic mutations using NGS method, according to the EMAST and MSI status.

           EMAST Status   MSI Status                                         
  -------- -------------- ------------ ------------- ----------- ----------- -------------
  EXO1     2 (2.6)        9 (12.2)     **0.025**     1 (1.1)     10 (17.2)   **\<0.001**
  EPCAM    0              4 (5.4)      **0.040**     0           4 (6.9)     **0.011**
  MSH2     0              17 (23.0)    **\<0.001**   9 (9.8)     8 (13.8)    0.451
  MSH6     6 (7.9)        12 (16.2)    0.117         8 (8.7)     10 (17.2)   0.117
  PCNA     0              0            \-            0           0           \-
  PMS1     2 (2.6)        2 (2.7)      0.978         0           4 (6.9)     **0.011**
  PMS2     2 (2.6)        1 (1.4)      0.576         3 (3.3)     0           0.165
  TGFBR2   5 (6.6)        15 (20.3)    **0.014**     8 (8.7)     12 (20.7)   **0.035**
  MLH1     0              4 (5.4)      **0.040**     4 (4.3)     0           0.107
  CTNNB1   3 (3.9)        4 (5.4)      0.672         7 (7.6)     0           **0.031**
  MSH3     4 (5.3)        19 (25.7)    **0.001**     13 (14.1)   10 (17.2)   0.607
  POLE     2 (2.6)        11 (14.9)    **0.008**     9 (9.8)     4 (6.9)     0.541
  AXIN1    1 (1.3)        11 (14.9)    **0.002**     6 (6.5)     6 (10.3)    0.401
  AXIN2    0              4 (5.4)      **0.040**     4 (4.3)     0           0.107
  BAX      3 (3.9)        15 (20.3)    **0.002**     6 (6.5)     12 (20.7)   **0.009**
  POLD1    3 (3.9)        9 (12.2)     0.064         6 (6.5)     6 (10.3)    0.401

EMAST: elevated microsatellite alterations at selected tetranucleotide repeats; MSI-H: microsatellite instability-high; MSS: microsatellite stable. Bold: statistically significant.
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###### 

Genetic mutations using NGS method, according to the EMAST/MSI status.

           EMAST/MSI Status   *p*-Value                       
  -------- ------------------ ----------- --------- --------- -------------
  EXO1     8 (23.5)           1 (2.5)     2 (8.3)   0         **0.001**
  EPCAM    4 (11.8)           0           0         0         **0.005**
  MSH2     8 (23.5)           9 (22.5)    0         0         **\<0.001**
  MSH6     8 (23.5)           4 (10.0)    2 (8.3)   4 (7.7)   **0.048**
  PCNA     0                  0           0         0         \-
  PMS1     2 (5.9)            0           2 (8.3)   0         0.281
  PMS2     0                  1 (2.5)     0         2 (3.8)   0.294
  TGFBR2   10 (29.4)          5 (12.5)    2 (8.3)   3 (5.8)   **0.003**
  MLH1     0                  4 (10.0)    0         0         0.281
  CTNNB1   0                  4 (10.0)    0         3 (5.8)   0.596
  MSH3     8 (23.5)           11 (27.5)   2 (8.3)   2 (3.8)   **0.002**
  POLE     4 (11.8)           7 (17.5)    0         2 (3.8)   **0.045**
  AXIN1    6 (17.6)           5 (12.5)    0         1 (1.9)   **0.003**
  AXIN2    0                  4 (10.0)    0         0         0.281
  BAX      10 (29.4)          5 (12.5)    2 (8.3)   1 (1.9)   **\<0.001**
  POLD1    6 (17.6)           3 (7.5)     0         3 (5.8)   0.055

Statistically significant; EMAST: elevated microsatellite alterations at selected tetranucleotide repeats; MSI-H: microsatellite instability-high; MSS: microsatellite stable. Bold: statistically significant.
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###### 

The patterns of initial recurrence of gastric cancer after curative surgery, according to EMAST and MSI status.

  -------------------------------------------------------------------------------------------------------
  Recurrence Patterns            EMAST (−)\   EMAST (+)\   *p*-Value   MSS\        MSI-H\     *p*-Value
                                 n = 217      n = 58                   n = 230     n = 45     
  ------------------------------ ------------ ------------ ----------- ----------- ---------- -----------
  Total recurrence               60 (27.6)    9 (15.5)     0.058       61 (26.5)   8 (17.8)   0.216

  Locoregional recurrence        13 (6.0)     4 (6.9)      0.763       15 (6.5)    2 (4.4)    0.597

  Distant metastasis             45 (20.7)    5 (8.6)      **0.034**   44 (19.1)   6 (13.3)   0.356

  Peritoneal dissemination       20 (9.2)     1 (1.7)      0.090       17 (7.4)    4 (8.9)    0.759

  Hematogenous metastasis        23 (10.6)    3 (5.2)      0.210       22 (9.6)    4 (8.9)    0.887

  Liver                          18 (8.3)     2 (3.4)                  16 (7.0)    4 (8.9)    

  Lung                           1 (0.5)      2 (3.4)                  3 (1.3)     0          

  Bone                           3 (1.4)      0                        3 (1.3)     0          

  Skin                           1 (0.5)      0                        1 (0.4)     0          

  Distant lymphatic recurrence   12 (5.5)     1 (1.7)      0.313       13 (5.7)    0          0.136

  Virchow's node                 1 (0.5)      0                        1 (0.4)     0          

  Para-aortic lymph node         12 (5.7)     1 (2.3)                  13 (5.7)    0          
  -------------------------------------------------------------------------------------------------------

Some patients had more than one initial recurrence pattern; EMAST: elevated microsatellite alterations at selected tetranucleotide repeats; MSI-H: microsatellite instability-high; MSS: microsatellite stable. Bold: statistically significant.
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###### 

The patterns of initial recurrence of gastric cancer after curative surgery, according to EMAST status.

  Recurrence Patterns            EMAST/MSI Status                                     
  ------------------------------ ------------------ ---------- ---------- ----------- -----------
  Total recurrence               0                  9 (31.0)   8 (50.0)   52 (25.9)   **0.001**
  Locoregional recurrence        0                  4 (13.8)   2 (12.5)   11 (5.5)    0.991
  Distant metastasis             0                  5 (17.2)   6 (37.5)   39 (19.4)   **0.014**
  Peritoneal dissemination       0                  1 (3.4)    4 (25.0)   16 (8.0)    **0.019**
  Hematogenous metastasis        0                  3 (10.3)   4 (25.0)   19 (9.5)    0.056
  Liver                          0                  2 (3.4)    4 (25.0)   14 (7.0)    
  Lung                           0                  2 (6.9)    0          1 (0.5)     
  Bone                           0                  0          0          3 (1.5)     
  Skin                           0                  0          0          1 (0.5)     
  Distant lymphatic recurrence   0                  1 (3.4)    0          12 (6.0)    0.127
  Virchow's node                 0                  0          0          1 (0.5)     
  Para-aortic lymph node         0                  1 (3.4)    0          12 (6.0)    

Some patients had more than one initial recurrence pattern; EMAST: elevated microsatellite alterations at selected tetranucleotide repeats; MSI-H: microsatellite instability-high; MSS: microsatellite stable. Bold: statistically significant.
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###### 

Multivariate Cox proportional-hazards model for the analysis of the overall survival and disease-free survival for gastric cancer patients after curative surgery.

  Risk Factors              Overall Survival   Disease-free Survival                                     
  ------------------------- ------------------ ----------------------- ----------- ------ -------------- -----------
  Age (y/o)                                                            0.204                             0.305
  \<45                      1.00                                                   1.00                  
  ≥45                       1.66               0.759--3.616                        1.47   0.705--3.054   
  Gender                                                               0.068                             0.206
  M                         1.00                                                   1.00                  
  F                         0.67               0.435--1.030                        0.77   0.505--1.159   
  Tumor size (cm)                                                      0.590                             0.622
  \<5                       1.00                                                   1.00                  
  ≥5                        1.11               0.755--1.638                        1.10   0.755--1.601   
  Lymphovascular invasion                                              **0.046**                         **0.045**
  Absent                    1.00                                                   1.00                  
  Present                   1.58               1.009--2.487                        1.57   1.010--2.433   
  Lauren's classification                                              **0.022**                         **0.033**
  Intestinal type           1.00                                                   1.00                  
  Diffuse type              1.55               1.064--2.268                        1.50   1.032--2.169   
  Pathological TNM stage                                               **0.001**                         **0.002**
  I                         1.00                                                   1.00                  
  II                        1.02               0.555--1.867                        1.05   0.581--1.895   
  III                       2.18               1.184--4.011                        2.18   1.208--3.935   
  EMAST status                                                         0.384                             0.490
  −                         1.00                                                   1.00                  
  \+                        1.22               0.781--1.900                        1.17   0.748--1.831   
  MSI status                                                           0.854                             0.986
  MSI-H                     1.00                                                   1.00                  
  MSS                       1.05               0.627--1.758                        1.01   0.598--1.688   

EMAST: elevated microsatellite alterations at selected tetranucleotide repeats; MSI: microsatellite instability; MSI-H: microsatellite instability-high; MSS: microsatellite stable. Bold: statistically significant.
